<HTML>
<HEAD>
<TITLE>8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">
<DIV style="font-size: 10pt">
<DIV style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): March 12, 2009</B>

<P style="font-size: 24pt" align="center"><B>NEUROBIOLOGICAL TECHNOLOGIES,
INC.<BR>
</B><FONT style="font-size: 10pt">(Exact name of registrant as
specified in its charter) </FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Delaware</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>000-23280</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>94-3049219</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>2000 Powell Street, Suite
800, Emeryville,<BR>
California<BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>94608</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(510) 595-6000</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>NOT
APPLICABLE<BR>
</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<DIV style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="left"><B>Item&nbsp;1.02. Termination of a
Material Definitive Agreement.</B>

<P style="font-size: 10pt; text-indent: 4%" align="left">On March&nbsp;12,
2009, Neurobiological Technologies, Inc. (the &#8220;Company&#8221;) notified
Abbott Laboratories (&#8220;Abbott&#8221;) of its intention to terminate the
License Agreement, dated as of March&nbsp;29, 2002, between the Company (as
successor of Empire Pharmaceuticals, Inc.) and Abbott, as amended (the
&#8220;Agreement&#8221;), effective as of June&nbsp;10, 2009. Under the
Agreement, Abbott granted the Company an exclusive worldwide license for all
human therapeutic indications for Viprinex (ancrod)&nbsp;and the Company had an
obligation to use commercially reasonable efforts to develop Viprinex for the
treatment of acute ischemic stroke. No early termination penalties were
incurred by the Company in connection with the termination of the Agreement.
Pursuant to the terms of the Agreement, the Company intends to return all
materials, studies and information relating to Viprinex to Abbott upon receipt
of the delivery instructions from Abbott.

<P style="font-size: 10pt" align="left"><B>Item&nbsp;5.02. Departure of
Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangement of Certain Officers.</B>

<P style="font-size: 10pt; text-indent: 4%" align="left">On March&nbsp;13,
2009, the Compensation Committee of the Board of Directors of the Company
approved the payment of compensation of $25,000 per month to William A.
Fletcher for his services as the Company&#8217;s Acting Chief Executive
Officer, effective retroactive to his appointment to this office on
January&nbsp;30, 2009.

<P style="font-size: 10pt" align="center"><B>SIGNATURE</B>

<P style="font-size: 10pt; text-indent: 4%" align="left">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.

<P style="font-size: 10pt" align="left">Dated: March&nbsp;18, 2009

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="48%">&nbsp;</TD>
  <TD width="4%">&nbsp;</TD>
  <TD width="48%">&nbsp;</TD>
 </TR>
<!-- End Table Head -->

<!-- Begin Table Body -->


 <TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD valign="top" align="left" colspan="2">NEUROBIOLOGICAL TECHNOLOGIES, INC.</TD>
 </TR>

 <TR valign="bottom">
  <TD valign="top"><DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV></TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">&nbsp;</TD>
 </TR>

 <TR valign="bottom">
  <TD valign="top"><DIV style="margin-left: 0px; text-indent: 0px"></DIV></TD>
  <TD align="left">By: &nbsp;</TD>
  <TD valign="top" align="left" style="border-bottom: 1px solid #000000"><FONT style="font-variant: small-caps">/s/ Matthew M. Loar </FONT></TD>
 </TR>

 <TR valign="bottom">
  <TD valign="top"><DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV></TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Matthew M. Loar</TD>
 </TR>
 <TR valign="bottom">
  <TD valign="top"><DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV></TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Vice President and Chief Financial Officer</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="font-size: 10pt" align="center">&nbsp;

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">2
</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c82802e8vk.htm", "description": "8-K", "secsgml_size_bytes": 7836}]
{"company-data": {"conformed-name": "NEUROBIOLOGICAL TECHNOLOGIES INC /CA/", "cik": "0000918112", "assigned-sic": "2836", "irs-number": "943049219", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-23280", "film-number": "09690698"}, "business-address": {"street1": "2000 POWELL STREET, SUITE 800", "city": "EMERYVILLE", "state": "CA", "zip": "94608", "phone": "510-595-6000"}, "mail-address": {"street1": "2000 POWELL STREET,  SUITE 800", "city": "EMERYVILLE", "state": "CA", "zip": "94608"}}
8-K
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): March 12, 2009
NEUROBIOLOGICAL TECHNOLOGIES,
INC.
(Exact name of registrant as
specified in its charter)
Delaware
000-23280
94-3049219
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
2000 Powell Street, Suite
800, Emeryville,
California
94608
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number,
including area code:
(510) 595-6000
NOT
APPLICABLE
(Former name or former address if changed since last report.)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.02. Termination of a
Material Definitive Agreement.
On March 12,
2009, Neurobiological Technologies, Inc. (the "Company") notified
Abbott Laboratories ("Abbott") of its intention to terminate the
License Agreement, dated as of March 29, 2002, between the Company (as
successor of Empire Pharmaceuticals, Inc.) and Abbott, as amended (the
"Agreement"), effective as of June 10, 2009. Under the
Agreement, Abbott granted the Company an exclusive worldwide license for all
human therapeutic indications for Viprinex (ancrod) and the Company had an
obligation to use commercially reasonable efforts to develop Viprinex for the
treatment of acute ischemic stroke. No early termination penalties were
incurred by the Company in connection with the termination of the Agreement.
Pursuant to the terms of the Agreement, the Company intends to return all
materials, studies and information relating to Viprinex to Abbott upon receipt
of the delivery instructions from Abbott.
Item 5.02. Departure of
Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangement of Certain Officers.
On March 13,
2009, the Compensation Committee of the Board of Directors of the Company
approved the payment of compensation of $25,000 per month to William A.
Fletcher for his services as the Company's Acting Chief Executive
Officer, effective retroactive to his appointment to this office on
January 30, 2009.
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.
Dated: March 18, 2009
NEUROBIOLOGICAL TECHNOLOGIES, INC.
By:
/s/ Matthew M. Loar
Matthew M. Loar
Vice President and Chief Financial Officer